Brief: Acer Therapeutics Enrolls First Patient In Its Phase 2A Clinical Trial Of Acer-801 For Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause
30/03/2022 13:52
March 30 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ENROLLS FIRST PATIENT IN ITS PHASE 2A
CLINICAL
TRIAL OF ACER-801 FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR
SYMPTOMS ASSOCIATED WITH MENOPAUSE
Source text for Eikon: ID:nGNX2t4WQ7
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31